Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age: Children’s Oncology Group study ARST0332.

Sheri L. Spunt(BVI (United States)), Alberto S. Pappo(St. Jude Children's Research Hospital), William H. Meyer(Lawrence Livermore National Laboratory), Lynn Million(VA Palo Alto Health Care System), Simon C. Kao(University of Iowa), Beth McCarville(St. Jude Children's Research Hospital), James R. Anderson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rose Anne Speights(St. Jude Children's Research Hospital), David M. Parham(Children's Hospital of Los Angeles), R. Lor Randall(University of California Davis Medical Center), Andrea Hayes‐Jordan(The University of Texas MD Anderson Cancer Center), Stephanie A. Terezakis(Johns Hopkins University), Suzanne L. Wolden(Memorial Sloan Kettering Cancer Center), Jennifer O. Black(Children's Hospital Colorado), Ellen Kawashima(Children's Oncology Group), Douglas S. Hawkins(Seattle Children's Hospital), Fran Laurie(University of Massachusetts Chan Medical School), Cheryl M. Coffin(University of Utah), Stephen X. Skapek(Duke University)
Journal of Clinical Oncology
May 20, 2014
Cited by 30


Related Papers